Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare effectiveness of ziprasidone treatment to current
treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric
Rating Scale (BPRS) scores versus baseline
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.